144 related articles for article (PubMed ID: 28419076)
1. In brief: Pancreatitis with eluxadoline (Viberzi) in patients without a gallbladder.
Med Lett Drugs Ther; 2017 Apr; 59(1519):70. PubMed ID: 28419076
[No Abstract] [Full Text] [Related]
2. Eluxadoline-Associated Pancreatitis in a Post-Cholecystectomy Patient: A Case Report.
Chhaparia A; Hammami MB; Vareedayah A; Schroeder K
Del Med J; 2017 Mar; 89(3):90-92. PubMed ID: 29894043
[TBL] [Abstract][Full Text] [Related]
3. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.
Özdener AE; Rivkin A
Drug Des Devel Ther; 2017; 11():2827-2840. PubMed ID: 29033544
[TBL] [Abstract][Full Text] [Related]
4. Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.
Gawron AJ; Bielefeldt K
Clin Gastroenterol Hepatol; 2018 Mar; 16(3):378-384.e2. PubMed ID: 28804032
[TBL] [Abstract][Full Text] [Related]
5. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
Am J Gastroenterol; 2017 Feb; 112(2):365-374. PubMed ID: 27922029
[TBL] [Abstract][Full Text] [Related]
6. Τ Eluxadoline for IBS-D.
Drug Ther Bull; 2017 Aug; 55(8):91-92. PubMed ID: 28808082
[No Abstract] [Full Text] [Related]
7. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
Liu R; Staller K
Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
[TBL] [Abstract][Full Text] [Related]
8. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
Fant RV; Henningfield JE; Cash BD; Dove LS; Covington PS
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1021-1029.e6. PubMed ID: 28167156
[TBL] [Abstract][Full Text] [Related]
9. Eluxadoline-induced pancreatitis occurring in an adult man without a prior cholecystectomy.
Shahid Z; Packard E; Groff A; Jain R
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31466958
[TBL] [Abstract][Full Text] [Related]
10. ▼ Eluxadoline for IBS-D.
Drug Ther Bull; 2017 Aug; 55(8):90-93. PubMed ID: 28808081
[TBL] [Abstract][Full Text] [Related]
11. Eluxadoline approved for irritable bowel syndrome with diarrhea.
Traynor K
Am J Health Syst Pharm; 2015 Jul; 72(13):1078. PubMed ID: 26092951
[No Abstract] [Full Text] [Related]
12. Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.
Keating GM
Drugs; 2017 Jun; 77(9):1009-1016. PubMed ID: 28493170
[TBL] [Abstract][Full Text] [Related]
13. Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder.
Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
Am J Gastroenterol; 2017 Oct; 112(10):1619-1620. PubMed ID: 28978951
[No Abstract] [Full Text] [Related]
14. Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
Med Lett Drugs Ther; 2016 Jan; 58(1485):4-5. PubMed ID: 26714241
[No Abstract] [Full Text] [Related]
15. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
Lembo AJ; Lacy BE; Zuckerman MJ; Schey R; Dove LS; Andrae DA; Davenport JM; McIntyre G; Lopez R; Turner L; Covington PS
N Engl J Med; 2016 Jan; 374(3):242-53. PubMed ID: 26789872
[TBL] [Abstract][Full Text] [Related]
16. Eluxadoline: First Global Approval.
Garnock-Jones KP
Drugs; 2015 Jul; 75(11):1305-10. PubMed ID: 26149369
[TBL] [Abstract][Full Text] [Related]
17. New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.
Corsetti M; Whorwell P
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):285-292. PubMed ID: 28276811
[TBL] [Abstract][Full Text] [Related]
18. Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.
Lacy BE; Chey WD; Cash BD; Lembo AJ; Dove LS; Covington PS
Am J Gastroenterol; 2017 Jun; 112(6):924-932. PubMed ID: 28417992
[TBL] [Abstract][Full Text] [Related]
19. Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder.
Harinstein L; Wu E; Brinker A
Aliment Pharmacol Ther; 2018 Mar; 47(6):809-815. PubMed ID: 29349789
[TBL] [Abstract][Full Text] [Related]
20. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE
Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
